PROF

$5.84+0.13 (+2.28%)

Market OpenAs of Mar 17, 6:54 PM UTC

Profound Medical Corp.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$5.84
Potential Upside
5%
Whystock Fair Value$6.13
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO sy...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$211.95M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.39
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-67.11%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
11.02

Recent News

TipRanks
Mar 14, 2026

Profound Medical reports CAPTAIN trial meets primary safety endpoint

Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic radical prostatectomy in men with organ-confined, intermediate-risk, Gleason Score 7 prostate cancer. CAPTAIN exceeded its enrollment target, treating 211 patients, instead of the initially planned 201 patients, by August 2025 at 20 sites in the United States, two in Canada and one in Europe. Baseline

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 6, 2026

Profound Medical Corp (PROF) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic ...

Profound Medical Corp (PROF) reports a 43% revenue increase and global expansion, while addressing operational challenges and aiming for cash flow positivity.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 6, 2026

Profound Medical Q4 Earnings Call Highlights

Profound Medical (NASDAQ:PROF) reported fourth-quarter 2025 revenue of $6.0 million, including $2.3 million in recurring revenue and $3.7 million from one-time capital equipment sales, according to management on the company’s earnings call. The company said Q4 revenue increased 43% from the prior-ye

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 5, 2026

Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of 0.00% and -21.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 2, 2026

ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

ARS Pharmaceuticals, Inc. (SPRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.